PEPG Trading Analysis - 10/30/2026 10:56 AM — TRU-SENTIMENT

News Headlines & Context:

Recent general-knowledge context for PEPG (PepGen Inc.), a clinical-stage biotech focused on oligonucleotide therapies for neuromuscular diseases:

• Q3 2026 pipeline update expected before year-end; no confirmed earnings date in provided data but fiscal year end was 2025-12-01 per fundamentals.
• Earlier 2026 disclosures noted ongoing Phase 1/2 trials for DMD and ALS candidates; binary clinical-readout risk remains a key catalyst.
• Sector-wide biotech volatility has been elevated; high-beta names like PEPG (beta 2.34) often amplify broad market moves.
• No specific partnership or FDA decision headlines retrieved for this run; context suggests sentiment is event-driven rather than fundamentals-driven.
• Headlines imply a wait-and-see stance, which aligns with the embedded options data showing balanced sentiment and no directional conviction.

Fundamental Analysis:

Based strictly on the provided FUNDAMENTALS data for PEPG:

• Trailing EPS is -1.30; company is unprofitable with no positive earnings. Trailing PE, forward PE, PEG, price-to-book all null.
• Revenue growth, gross/operating/net margins, ROE, debt-to-equity, and free cash flow are null — not disclosed in data.
• Market cap is $154,796,100 with shares outstanding of 69,260,000; micro-cap classification.
• Institutional ownership is only 7.50%, indicating thin sponsor base and potential liquidity fragility.
• Dividend yield 0.00; no dividend. Beta 2.34 vs broad market — high systematic risk.
• 52-week range $1.31 to $7.80; current price ~$2.44 is near lower third of annual range.
• Historical volatility 83.25%; average volume 972,000 vs 20-day avg 775,378.
• Analyst target mean price and recommendation key are null — no street consensus in data.
• Fundamentals (loss-making, tiny cap, low institutions) diverge from any bullish technical hope; data shows weak structural support.

Current Market Position:

Current price per indicators is $2.44 (2026-10-29 close $2.44). Minute bars show 2026-10-29 open $2.54, high $2.62, low $2.42, close $2.44. By 2026-10-30 10:25, price fell to $2.23 (open $2.54 prior session, last bar low $2.22). Intraday momentum is downward: from $2.57 at 09:30 on 10-29 to $2.23 at 10:25 on 10-30, a decline of ~13%. Volume spiked to 29,347 at 10:05 10-30 vs ~1,000–2,000 earlier, confirming distribution.

Technical Analysis:

• Price $2.44 below SMA 5 ($2.51), SMA 20 ($2.52), and SMA 50 ($2.77) — bearish alignment, no golden cross.
• RSI 43.40: sub-50 momentum, not oversold (no <30), weak bias.
• MACD -0.03 with signal -0.03 and hist -0.01: marginally negative, no bull cross.
• Bollinger mid $2.52, lower $2.21; price near lower band — slight compression, no squeeze signal.
• 30-day range high $3.03, low $2.23; current $2.44 sits at ~17% above low, 80% below high.

True Sentiment Analysis (Delta 40-60 Options):

Per embedded TRUE SENTIMENT OPTIONS (2026-10-30 10:55):

Call Volume: $0.00 (0.0%) Put Volume: $0.00 (0.0%) Total: $0.00

• Sentiment labeled "Balanced" with 0 directional trades filtered (filter ratio 0.0%).
• No call or put dollar conviction; pure directional positioning absent.
• Aligns with option spread advice: "Balanced sentiment - no clear directional bias."
• No divergence vs technicals (both non-bullish, neutral-to-soft).

Key Price Levels (observational only):